- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Nov 2025 | 7 Nov 2025 |
| Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve the financial results for the period ended September 30 2025 and 2nd Interim dividend for the Financial Year ending 2025-26 Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business: Declared second interim dividend of Rs.1.50 (Rupees one and fifty paise only) (75%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2025-26. The date for taking on record of its shareholders eligible for the purpose of payment ofsecond interim dividend i.e., record date I s fixed as Thursday, the 20th day of November 2025. The payment of said interim dividend will start from November 28, 2025. (As Per BSE Notice Dated on 14.11.2025) | ||
| Board Meeting | 25 Sep 2025 | 23 Sep 2025 |
| Outcome of Board Meeting | ||
| Board Meeting | 12 Aug 2025 | 4 Aug 2025 |
| Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve the Un-audited Financial Results for the quarter ended 30th June 2025 and declaration of Interim Dividend for the FY25-26. Outcome of Board Meeting (As Per BSE Announcement Dated on: 12/08/2025) | ||
| Board Meeting | 23 Jul 2025 | 23 Jul 2025 |
| Outcome of the Board Meeting held on 23rd July, 2025 | ||
| Board Meeting | 28 May 2025 | 12 May 2025 |
| This is to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, the 28 th day of May 2025 inter-alia to consider and approve the Audited Financial Results for the quarter and year ended 31 st March, 2025 and other items of business and related matters. Please further note that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time-to-time TRADING WINDOW for dealing in the securities of the Company by the Employee(s), connected persons and their immediate relatives will be closed from 13 th May, 2025 till 48 hours after the declaration of financial results Audited Financial Results for the quarter and year ended 31st March, 2025 Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 (As Per BSE Announcement Dated on: 28/05/2025) | ||
| Board Meeting | 12 Feb 2025 | 30 Jan 2025 |
| NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve the unaudited financial results for the quarter and nine months ended 31st December 2024 and 3rd Interim Dividend if any Unaudited Financial Results for the quarter and nine months ended December 31, 2024 (As Per Bse Announcement Dated on 12.02.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.